DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS BLUNTED BY LATE SODIUM CURRENT INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS
Nicola Maurea(Cancer Institute (WIA)), Carlo G. Tocchetti(Federico II University Hospital), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Clemente Cipresso(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenica Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudio Arra(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Aldo Giudice(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Piscopo(University of Cagliari)
Cited by 1
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364